Michael Singer

Neutrolis, Inc. is a biotechnology company located in North Cambridge, MA. The company develops first-in-class therapies that target neutrophils and their pathogenic products, including nets. Neutrolis proprietary platform, Chromatinase™, is based on the naturally occurring enzymes that break down the extracellular chromatin that form nets. The company's lead product, NTR-441, is a patented, first-in-class, engineered DNASE1L3 analog with potential application in COVID-19, ARDS, lupus, rheumatoid arthritis, systemic sclerosis, and other net-mediated diseases. Neutrolis has received two competitive LabCentral Golden Ticket awards from Pfizer and Bristol-Myers Squibb. The company was founded by Abdul Hakkim and Toby Fox. Toby Fox has been the CEO since incorporation.

Anodyne Nanotech, Inc. operates as a preclinical-stage biotech company. It develops differentiated and transdermal forms of high-value drugs. The company is headquartered in Boston, MA.

Anodyne Nanotech, Inc. operates as a preclinical-stage biotech company. It develops differentiated and transdermal forms of high-value drugs. The company is headquartered in Boston, MA.

Cartesian Therapeutics, Inc. manufacturers biological products. The company was founded by Murat Kalayoglu and Michael Singer in 2016 and is headquartered in Gaithersburg, MD.

Cartesian Therapeutics, Inc. manufacturers biological products. The company was founded by Murat Kalayoglu and Michael Singer in 2016 and is headquartered in Gaithersburg, MD.

Anodyne Nanotech, Inc. operates as a preclinical-stage biotech company. It develops differentiated and transdermal forms of high-value drugs. The company is headquartered in Boston, MA.

Neutrolis, Inc. is a biotechnology company located in North Cambridge, MA. The company develops first-in-class therapies that target neutrophils and their pathogenic products, including nets. Neutrolis proprietary platform, Chromatinase™, is based on the naturally occurring enzymes that break down the extracellular chromatin that form nets. The company's lead product, NTR-441, is a patented, first-in-class, engineered DNASE1L3 analog with potential application in COVID-19, ARDS, lupus, rheumatoid arthritis, systemic sclerosis, and other net-mediated diseases. Neutrolis has received two competitive LabCentral Golden Ticket awards from Pfizer and Bristol-Myers Squibb. The company was founded by Abdul Hakkim and Toby Fox. Toby Fox has been the CEO since incorporation.

Anodyne Nanotech, Inc. operates as a preclinical-stage biotech company. It develops differentiated and transdermal forms of high-value drugs. The company is headquartered in Boston, MA.

Anodyne Nanotech, Inc. operates as a preclinical-stage biotech company. It develops differentiated and transdermal forms of high-value drugs. The company is headquartered in Boston, MA.

Anodyne Nanotech, Inc. operates as a preclinical-stage biotech company. It develops differentiated and transdermal forms of high-value drugs. The company is headquartered in Boston, MA.

Pykus Therapeutics, Inc. engages in the development of a dissolvable intraocular surgical device. It offers novel polymer that provides retinal tamponade. The company was founded by James Stefater and Tomasz Stryjewski and is headquartered in Boston, MA.

Pykus Therapeutics, Inc. engages in the development of a dissolvable intraocular surgical device. It offers novel polymer that provides retinal tamponade. The company was founded by James Stefater and Tomasz Stryjewski and is headquartered in Boston, MA.

Pykus Therapeutics, Inc. engages in the development of a dissolvable intraocular surgical device. It offers novel polymer that provides retinal tamponade. The company was founded by James Stefater and Tomasz Stryjewski and is headquartered in Boston, MA.

Pykus Therapeutics, Inc. engages in the development of a dissolvable intraocular surgical device. It offers novel polymer that provides retinal tamponade. The company was founded by James Stefater and Tomasz Stryjewski and is headquartered in Boston, MA.

Anodyne Nanotech, Inc. operates as a preclinical-stage biotech company. It develops differentiated and transdermal forms of high-value drugs. The company is headquartered in Boston, MA.